Deutsche Bank AG cut its holdings in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 64.2% in the 4th quarter, HoldingsChannel reports. The fund owned 26,085 shares of the company’s stock after selling 46,854 shares during the period. Deutsche Bank AG’s holdings in Apellis Pharmaceuticals were worth $343,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of APLS. Flinton Capital Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the fourth quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Apellis Pharmaceuticals by 159.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,903 shares of the company’s stock worth $38,000 after acquiring an additional 1,785 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Apellis Pharmaceuticals by 35.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock worth $124,000 after acquiring an additional 2,440 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Apellis Pharmaceuticals by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock worth $161,000 after acquiring an additional 9,541 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Apellis Pharmaceuticals by 15.3% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,467 shares of the company’s stock worth $164,000 after acquiring an additional 1,659 shares in the last quarter. 51.16% of the stock is owned by institutional investors.
Shares of APLS stock opened at $19.10 on Friday. Apellis Pharmaceuticals Inc has a 52-week low of $11.45 and a 52-week high of $24.84. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -8.16 and a beta of 0.44.
Several research firms have recently commented on APLS. Cantor Fitzgerald set a $57.00 target price on shares of Apellis Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 28th. Zacks Investment Research raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Finally, Robert W. Baird initiated coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, March 28th. They set an “outperform” rating and a $45.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Apellis Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $41.83.
In other news, major shareholder Morningside Venture Investment acquired 441,176 shares of Apellis Pharmaceuticals stock in a transaction on Monday, March 11th. The stock was acquired at an average cost of $17.00 per share, with a total value of $7,499,992.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 9.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4352894/deutsche-bank-ag-sells-46854-shares-of-apellis-pharmaceuticals-inc-apls.html.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Recommended Story: Trading Strategy Methods for Individual Investors
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.